{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:14:31Z","timestamp":1789031671900,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00277-024-05862-1","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T07:46:41Z","timestamp":1722239201000},"page":"3691-3699","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Development of a clinical prognostic model for primary plasma cell leukemia patients treated with novel agents: a multicenter retrospective cohort study"],"prefix":"10.1007","volume":"103","author":[{"given":"Jingjing","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqi","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuliang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingnan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guitao","family":"Jie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxia","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"issue":"2","key":"5862_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41408-021-00414-6","volume":"11","author":"SA Tuazon","year":"2021","unstructured":"Tuazon SA, Holmberg LA, Nadeem O et al (2021) A clinical perspective on plasma cell leukemia; current status and future directions[J]. Blood Cancer J 11(2):23","journal-title":"Blood Cancer J"},{"key":"5862_CR2","doi-asserted-by":"crossref","unstructured":"Fernandez DLC, Kyle R, Rosinol L et al Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage[J]. Blood Cancer J 2021, 11(12):192","DOI":"10.1038\/s41408-021-00587-0"},{"key":"5862_CR3","doi-asserted-by":"crossref","unstructured":"Musto P, Wasch R Plasma cell leukemia: another piece of the puzzle[J]. Haematol 2023, 108(4):941\u2013944","DOI":"10.3324\/haematol.2022.281432"},{"key":"5862_CR4","doi-asserted-by":"crossref","unstructured":"Kaiser M A double punch for plasma cell leukemia[J]. Haematol 2023, 108(4):939\u2013940","DOI":"10.3324\/haematol.2022.281353"},{"issue":"27","key":"5862_CR5","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1200\/JCO.21.01217","volume":"40","author":"OBD Hofste","year":"2022","unstructured":"Hofste OBD, Kuiper R, van Duin M et al (2022) Identification of high-risk multiple myeloma with a plasma cell leukemia-like Transcriptomic Profile[J]. J Clin Oncol 40(27):3132\u20133150","journal-title":"J Clin Oncol"},{"key":"5862_CR6","doi-asserted-by":"crossref","unstructured":"Papadhimitriou SI, Terpos E, Liapis K et al The Cytogenetic Profile of primary and secondary plasma cell leukemia: etiopathogenetic perspectives, prognostic impact and clinical relevance to newly diagnosed multiple myeloma with Differential circulating Clonal plasma Cells[J]. Biomedicines,2022,10(2).","DOI":"10.3390\/biomedicines10020209"},{"key":"5862_CR7","doi-asserted-by":"crossref","unstructured":"Lee Y, Yun J, Jeong D et al Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma[J]. Leuk Lymphoma 2022, 63(2):385\u2013394","DOI":"10.1080\/10428194.2021.1983568"},{"issue":"1","key":"5862_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11912-019-0754-x","volume":"21","author":"MT Gundesen","year":"2019","unstructured":"Gundesen MT, Lund T, Moeller H et al (2019) Plasma cell leukemia: definition, presentation, and Treatment[J]. Curr Oncol Rep 21(1):8","journal-title":"Curr Oncol Rep"},{"key":"5862_CR9","doi-asserted-by":"crossref","unstructured":"Jelinek T, Bezdekova R, Zihala D et al More than 2% of circulating Tumor plasma cells defines plasma cell leukemia-like multiple Myeloma[J]. J Clin Oncol 2023, 41(7):1383\u20131392","DOI":"10.1200\/JCO.22.01226"},{"key":"5862_CR10","doi-asserted-by":"crossref","unstructured":"van de Donk N How we manage newly diagnosed multiple myeloma with circulating Tumor Cells[J]. J Clin Oncol 2023, 41(7):1342\u20131349","DOI":"10.1200\/JCO.22.02114"},{"key":"5862_CR11","doi-asserted-by":"crossref","unstructured":"Sant M, Allemani C, Tereanu C et al Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project[J]. Blood 2010, 116(19):3724\u20133734","DOI":"10.1182\/blood-2010-05-282632"},{"issue":"1","key":"5862_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.14735\/amko201947","volume":"32","author":"M Zapletalova","year":"2019","unstructured":"Zapletalova M, Krejci D, Jarkovsky J et al (2019) Epidemiology of plasma cell leukemia in the Czech Republic[J]. Klin Onkol 32(1):47\u201351","journal-title":"Klin Onkol"},{"key":"5862_CR13","doi-asserted-by":"crossref","unstructured":"Mina R, Joseph NS, Kaufman JL et al Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents[J]. Cancer 2019, 125(3):416\u2013423","DOI":"10.1002\/cncr.31718"},{"issue":"5","key":"5862_CR14","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/ajh.26891","volume":"98","author":"E Katodritou","year":"2023","unstructured":"Katodritou E, Kastritis E, Dalampira D et al (2023) Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: a multicenter study by the Greek myeloma study group[J]. Am J Hematol 98(5):730\u2013738","journal-title":"Am J Hematol"},{"key":"5862_CR15","doi-asserted-by":"crossref","unstructured":"Nandakumar B, Kumar SK, Dispenzieri A et al Clinical characteristics and outcomes of patients with primary plasma cell leukemia in the era of Novel Agent Therapy[J]. Mayo Clin Proc 2021, 96(3):677\u2013687","DOI":"10.1016\/j.mayocp.2020.06.060"},{"key":"5862_CR16","doi-asserted-by":"crossref","unstructured":"van de Donk N, Minnema MC, van der Holt B et al Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12\/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study[J]. Lancet Oncol,2023,24(10):1119\u20131133","DOI":"10.1016\/S1470-2045(23)00405-9"},{"issue":"6","key":"5862_CR17","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/bjh.15092","volume":"180","author":"A Jurczyszyn","year":"2018","unstructured":"Jurczyszyn A, Radocha J, Davila J et al (2018) Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients[J]. Br J Haematol 180(6):831\u2013839","journal-title":"Br J Haematol"},{"issue":"11","key":"5862_CR18","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1080\/10428194.2022.2086250","volume":"63","author":"M Saburi","year":"2022","unstructured":"Saburi M, Sakata M, Takata H et al (2022) Poor clinical outcome of elderly patients with primary plasma cell leukemia treated with novel agents: real-world experience[J]. Leuk Lymphoma 63(11):2691\u20132695","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"5862_CR19","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1080\/10428194.2022.2098290","volume":"63","author":"W Yan","year":"2022","unstructured":"Yan W, Fan H, Xu J et al (2022) The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria[J]. Leuk Lymphoma 63(12):2955\u20132964","journal-title":"Leuk Lymphoma"},{"key":"5862_CR20","doi-asserted-by":"crossref","unstructured":"Katodritou E, Terpos E, Delimpasi S et al Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group[J]. Blood Cancer J 2018, 8(3):31","DOI":"10.1038\/s41408-018-0059-6"},{"key":"5862_CR21","doi-asserted-by":"crossref","unstructured":"Jung SH, Kim K, Yoon SE et al Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party[J]. Blood Cancer J 2022, 12(11):157","DOI":"10.1038\/s41408-022-00755-w"},{"issue":"4","key":"5862_CR22","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1080\/10428194.2023.2171266","volume":"64","author":"C Pena","year":"2023","unstructured":"Pena C, Riva E, Schutz N et al (2023) Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group[J]. Leuk Lymphoma 64(4):816\u2013821","journal-title":"Leuk Lymphoma"},{"key":"5862_CR23","unstructured":"Li WJ, Wang FR, Wen L et al [The clinical characteristics of patients with primary plasma cell leukemia and the efficacy of novel agents and hematopoietic stem cell transplantation][J]. Zhonghua Nei Ke Za Zhi 2020, 59(10):801\u2013806"},{"key":"5862_CR24","doi-asserted-by":"crossref","unstructured":"Lawless S, Iacobelli S, Knelange NS et al Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia. Dynamic Prediction modeling[J] Haematol 2023, 108(4):1105\u20131114","DOI":"10.3324\/haematol.2021.280568"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05862-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05862-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05862-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T09:18:47Z","timestamp":1724836727000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05862-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["5862"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05862-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,29]]},"assertion":[{"value":"25 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}